ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2

Overview

About this study

The purpose of this study is to continue to measure the safety, tolerability, and durability of treatment effect in subjects with Narcolepsy Type 1 (NT1) or Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Was eligible for and has completed end of treatment visit of ALKS 2680 eligible parent study in NT1 or NT2. The current eligible studies are ALKS 2680-201 (Vibrance-1) and ALKS 2680-202 (Vibrance-2)
  • Is willing and able, and in the opinion of the treating physician can safely discontinue any medications prescribed for the management of narcolepsy symptoms, as applicable, for 5 half-lives prior to Day 1 (for re-entry subjects), and for the duration of study (for all subjects)

Exclusion Criteria:

  • Developed a new clinically significant health condition, ECG or laboratory abnormality, in the opinion of the Investigator or Sponsor, may impact the subject's participation in the study
  • Is currently pregnant, breastfeeding, or planning to become pregnant during the study
  • Is currently enrolled in another clinical study (other than the parent study) or used any investigational drug or device within 30 days prior to Screening

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 2/17/2025. Questions regarding updates should be directed to the study team contact.
 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Chad Ruoff, M.D.

Open for enrollment

Contact information:

Gabrielle Montefiore

(480) 574-1288

montefiore.gabrielle@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20589899

Mayo Clinic Footer